Department of Neuropediatrics, Children's Hospital of the University of Toulouse, 330 Great Britain Avenue, TSA 70034 Toulouse, France.
Faculty of Medicine, Epidemiology Department, University Hospital of Toulouse, 37 Allées Jules Guesde, 31073 Toulouse, France.
Neuromuscul Disord. 2019 Feb;29(2):114-126. doi: 10.1016/j.nmd.2018.10.002. Epub 2018 Oct 31.
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a rare autosomal recessive neuromuscular disorder characterized by progressive motor and respiratory decline during the first year of life. Early and late-onset cases have recently been reported, although not meeting the established diagnostic criteria, these cases have been genotyped. We thus conducted a national multicenter observational retrospective study to determine the prognosis of children with SMARD1 according to their phenotype. We recorded all known French pediatric cases with mutations identified on the immunoglobulin μ-binding protein 2 gene and the presence of respiratory symptoms. Thirty centers provided 22 observations. A diaphragmatic palsy was diagnosed 1.5 months (p = 0.02) after first respiratory symptoms, and hypotonia preceded areflexia by 4 months (p = 0.02). Early onset of symptoms leading to specialist consultation before the age of 3 months was associated with a significantly worse prognosis (p < 0.01). Among the 6 patients who were still alive, all were tracheostomized. Only one case survived beyond 2 years without artificial ventilation. The remaining patients died at a median age of 7 months. Our results may help pediatricians to provide medical information to parents and improve the decision-making process of setting up life support.
1 型脊髓性肌萎缩伴发进行性呼吸窘迫症(SMARD1)是一种罕见的常染色体隐性神经肌肉疾病,其特征是在生命的第一年中进行性运动和呼吸功能下降。尽管最近已经报道了早发和迟发型病例,但这些病例并未满足既定的诊断标准,这些病例已进行了基因分型。因此,我们进行了一项全国多中心回顾性观察研究,根据患者的表型来确定 SMARD1 患儿的预后。我们记录了所有已知的法国儿科病例,这些病例均具有免疫球蛋白 μ 结合蛋白 2 基因的突变和存在呼吸症状。30 个中心提供了 22 个观察结果。膈肌麻痹在首次出现呼吸症状后 1.5 个月(p=0.02)诊断,而低张力比无反射早 4 个月(p=0.02)。症状早期发病,在 3 个月前就诊于专家,与预后显著较差相关(p<0.01)。在仍存活的 6 名患者中,所有患者均接受了气管切开术。只有 1 例在没有人工通气的情况下存活超过 2 年。其余患者的中位年龄为 7 个月死亡。我们的结果可能有助于儿科医生向家长提供医疗信息,并改善建立生命支持的决策过程。